Omega Diagnostics Group PLC (ODX) is a leading medical instruments & supplies business based in the UK. It opened the day at 51.31p after a previous close of 52p. During the day the price has varied from a low of 48p to a high of 52.4p. The latest price was 51.5p (25 minute delay). Omega Diagnostics Group is listed on the London Stock Exchange (LSE) and employs 152 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Omega Diagnostics Group's share price has had significant positive movement.
Its last market close was 98.5p, which is 86.19% up on its pre-crash value of 13.6p and 1,541.67% up on the lowest point reached during the March crash when the shares fell as low as 6p.
If you had bought £1,000 worth of Omega Diagnostics Group shares at the start of February 2020, those shares would have been worth £451.50 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £6,588.63.
|52-week range||5.926p - 126.95p|
|50-day moving average||52.3971p|
|200-day moving average||62.9107p|
|Wall St. target price||27p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||0.7p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 month (2020-12-22)||6.19%|
|3 months (2020-10-22)||-44.92%|
|6 months (2020-07-22)||-14.17%|
Valuing Omega Diagnostics Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omega Diagnostics Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Omega Diagnostics Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Omega Diagnostics Group shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Omega Diagnostics Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £838,895.
The EBITDA is a measure of a Omega Diagnostics Group's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£8.5 million|
|Gross profit TTM||£6.3 million|
|Return on assets TTM||-3.94%|
|Return on equity TTM||-32.06%|
|Market capitalisation||£111.6 million|
TTM: trailing 12 months
We're not expecting Omega Diagnostics Group to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Omega Diagnostics Group's shares were split on a 1:40 basis on 31 August 2007. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Omega Diagnostics Group shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Omega Diagnostics Group shares which in turn could have impacted Omega Diagnostics Group's share price.
Over the last 12 months, Omega Diagnostics Group's shares have ranged in value from as little as 5.926p up to 126.95p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Omega Diagnostics Group's is 3.646. This would suggest that Omega Diagnostics Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries, Africa, and the Middle East. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases. This segment's product includes 69 CE-marked allergens. The Food Intolerance segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides CNS laboratory services that offer clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Infectious Diseases and Other segment is involved in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment's products include VISITECT CD4, an in-vitro diagnostic test, which is used in the management of patients with pre-diagnosed HIV infection, as well as develops and manufactures COVID-19 antibody and antigen tests. The company offers its products to hospitals, clinics, and laboratories through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.